Mile­stone Mon­day for Im­mat­ics’ Bris­tol My­ers-al­lied cell ther­a­py and 2sev­en­ty bio’s No­vo-part­nered he­mo­phil­ia A work

No­vo Nordisk is pony­ing up $15 mil­lion as part of 2sev­en­ty bio’s work on a pre­clin­i­cal gene ther­a­py can­di­date for he­mo­phil­ia A. Sep­a­rate­ly, Bris­tol My­ers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER